- Company Directors - W
- Wang Susan
Insider Trading History of Wang Susan
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Wang Susan since 2007.
The trader's CIK number is 1246409.
At the time of the last reporting, Wang Susan was the Director of Nektar Therapeutics. (stock ticker symbol NKTR).
Also see all insider trading activities at Nektar Therapeutics.
Note that in the past
WANG SUSAN also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Avanex Corp (AVNX) by Wang Susan
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2007 | AVNX | 0 | $0 | 0 | $0 | 10,000 | $10 |
Yearly summary of insider trading at Altera Corp (ALTR) by Wang Susan
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2013 | ALTR | 0 | $0 | 55,833 | $1,884,084 | 59,843 | $1,187,567 |
| 2012 | ALTR | 0 | $0 | 10,000 | $355,040 | 14,370 | $190,000 |
| 2011 | ALTR | 0 | $0 | 0 | $0 | 5,000 | $0 |
| 2010 | ALTR | 0 | $0 | 10,000 | $373,920 | 13,334 | $190,000 |
| 2009 | ALTR | 0 | $0 | 0 | $0 | 1,667 | $0 |
Yearly summary of insider trading at Cirrus Logic, Inc. (CRUS) by Wang Susan
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2015 | CRUS | 0 | $0 | 42,132 | $1,244,705 | 22,687 | $347,337 |
Yearly summary of insider trading at Nektar Therapeutics (NKTR) by Wang Susan
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2015 | NKTR | 0 | $0 | 115,000 | $1,657,292 | 115,000 | $780,674 |
| 2011 | NKTR | 0 | $0 | 0 | $0 | 10,000 | $0 |
| 2008 | NKTR | 0 | $0 | 0 | $0 | 5,000 | $0 |
Insider trading activities at 4 companies by Wang Susan:
1. Avanex Corp (AVNX)
2. Altera Corp (ALTR)
3. Cirrus Logic, Inc. (CRUS)
4. Nektar Therapeutics (NKTR)
Table 1. Insider trading of Avanex Corp (AVNX) by Wang Susan
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2007-11-03 | AVNX | Option Ex | 10,000 | .00 | 10 |
Table 2. Insider trading of Altera Corp (ALTR) by Wang Susan
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2013-05-16 | ALTR | Option Ex | 55,833 | 21.27 | 1,187,567 |
| 2013-05-16 | ALTR | Sale | 55,833 | 33.74 | 1,884,084 |
| 2013-05-06 | ALTR | Option Ex | 4,010 | .00 | 0 |
| 2012-07-31 | ALTR | Option Ex | 10,000 | 19.00 | 190,000 |
| 2012-07-31 | ALTR | Sale | 10,000 | 35.50 | 355,040 |
| 2012-05-13 | ALTR | Option Ex | 4,370 | .00 | 0 |
| 2011-05-13 | ALTR | Option Ex | 5,000 | .00 | 0 |
| 2010-12-10 | ALTR | Sale | 10,000 | 37.39 | 373,920 |
| 2010-12-10 | ALTR | Option Ex | 10,000 | 19.00 | 190,000 |
| 2010-05-13 | ALTR | Option Ex | 3,334 | .00 | 0 |
| 2009-05-13 | ALTR | Option Ex | 1,667 | .00 | 0 |
Table 3. Insider trading of Cirrus Logic, Inc. (CRUS) by Wang Susan
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2015-02-23 | CRUS | Option Ex | 22,687 | 15.31 | 347,337 |
| 2015-02-23 | CRUS | Sale | 42,132 | 29.54 | 1,244,705 |
Table 4. Insider trading of Nektar Therapeutics (NKTR) by Wang Susan
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2015-11-18 | NKTR | Option Ex | 20,372 | 6.75 | 137,612 |
| 2015-11-19 | NKTR | Option Ex | 15,128 | 5.14 | 77,757 |
| 2015-11-20 | NKTR | Option Ex | 49,500 | 7.19 | 355,905 |
| 2015-11-18 | NKTR | Sale | 20,372 | 15.00 | 305,580 |
| 2015-11-19 | NKTR | Sale | 15,128 | 15.02 | 227,222 |
| 2015-11-20 | NKTR | Sale | 49,500 | 15.02 | 743,490 |
| 2015-06-29 | NKTR | Sale | 30,000 | 12.70 | 381,000 |
| 2015-06-29 | NKTR | Option Ex | 30,000 | 6.98 | 209,400 |
| 2011-03-07 | NKTR | Option Ex | 10,000 | .00 | 0 |
| 2008-11-14 | NKTR | Option Ex | 5,000 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Wang Susan
(Director of Nektar Therapeutics at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.